News | Renal Denervation | October 11, 2016

New NIH Awards will Enhance Understanding of How Nerves Control Organ Function

NIH funds over $20 million in peripheral nervous system research

October 11, 2016 — Awards from the National Institutes of Health’s Common Fund are supporting research on the peripheral nervous system, in hopes of finding new ways to treat conditions such as asthma, diabetes and nausea. The new awards total more than $20 million in fiscal year 2016, and go to 27 multidisciplinary research teams through the Stimulating Peripheral Activity to Relieve Conditions (SPARC) program. The SPARC program plans to support awards totaling approximately $238M through fiscal year 2021, pending available funds.

This year’s awards encompass a wide range of projects intended to resolve existing knowledge gaps and technology limitations. In addition to treatment research, other projects focus on various organ systems, including heart, lung, stomach/intestine, colon, adipose tissue, spleen, bladder and pancreas.  

SPARC focuses on understanding peripheral nerves — nerves that connect the brain and spinal cord to the rest of the body — and how their electrical signals control internal organ function. Modulation of these control signals is a potentially powerful way to treat common conditions and diseases such as rheumatoid arthritis and heart failure. Methods and medical devices that modulate peripheral nerve activity are becoming available, but more research to fully understand how these therapies act on a target organ’s cells is needed. Such understanding could help to explain and resolve why a particular therapy may be effective in one individual, but not in another, thereby making these therapies effective for more people.

“SPARC fosters synergistic, multidisciplinary collaborations to advance this rapidly developing research area with high potential to enable new and improved treatments,” said James M. Anderson, M.D., Ph.D., director of the NIH Division of Program Coordination, Planning and Strategic Initiatives, which oversees the NIH Common Fund. “The insights gained from these cutting-edge, collaborative projects will accelerate development of methods and devices to treat diseases for which conventional therapies fall short.”

The 2016 awardees will work collectively as a consortium to address the goals and aims of SPARC. Biological projects will develop detailed anatomical and functional maps that illustrate how peripheral nerves control organ function, while technology development projects will create or improve tools to measure and manipulate nerve-organ interactions and isolate their functions. Additional projects include collaborations between private sector scientists and academic researchers, intended to expedite the development of new therapeutic strategies.

Going forward, the SPARC program will leverage expertise from many different sources — not only academic laboratories, but also independent inventors, start-ups, small and large businesses, and international organizations. Data and tools developed in the SPARC program will be shared through a central online resource. 

“The SPARC program invests in high-risk, goal-driven projects to discover the underlying mechanisms and pathways by which the peripheral nervous system controls internal organ function,” said SPARC Program Manager Gene Civillico, Ph.D. “This is achieved through a unique program management structure that allows SPARC to swiftly adopt new breakthroughs and emerging technologies, and nimbly incorporate ideas and expertise. These awards have the potential to catalyze next-generation neuromodulation therapies that could bring improved specificity for patients over both drug therapies and previous-generation devices.”

SPARC is funded through the NIH Common Fund and managed by the NIH Office of the Director, in partnership with the National Center for Advancing Translational Sciences, the National Institute of Biomedical Imaging and Bioengineering, the National Institute of Diabetes and Digestive and Kidney Diseases and the National Institute of Neurological Disorders and Stroke. The fiscal year 2016 funding will be issued via NIH Other Transaction and Cooperative Agreement award mechanisms.

For more information: www.nih.gov

Related Content

Vagal Maneuvers With Supraventricular Tachycardia

Image courtesy of ACLS Certification Institute

Feature | EP Lab | December 05, 2018
Supraventricular tachycardia (SVT) is a common heart abnormality that presents as a fast heart rate. SVT is a generic...
Societies Publish New Guidance for Treatment of Slow, Irregular Heartbeats
News | EP Lab | November 09, 2018
The American College of Cardiology (ACC), the American Heart Association (AHA) and the Heart Rhythm Society (HRS)...
A view of the EPD Solutions catheter ablation system image guidance. It displays the catheter within a pre-acquired 3D segmented CT image. The D700 system provides a real-time lesion assessment tool that predicts transmurality and permanency of lesions, pre- and immediately post-ablation.

A view of the EPD Solutions catheter ablation system image guidance. It displays the catheter within a pre-acquired 3D segmented CT image. The D700 system provides a real-time lesion assessment tool that predicts transmurality and permanency of lesions, pre- and immediately post-ablation.

News | EP Lab | June 05, 2018
June 5, 2018 — Philips Healthcare has signed an agreement to acquire EPD Solutions, a provider of image-guidance in c
A recent study shows the Baylis NRG radiofrequency (RF) Transseptal puncture catheter has a lower incidence of embolism in EP cases.
News | EP Lab | May 21, 2018
May 21, 2018 — A recent study published in Heart and Vessels has found that the use of the Baylis Medical NR
Myocarditis is an Under-recognized Etiology of Symptomatic Premature Ventricular Arrhythmia (PVCs). #HRS #HRS2018
News | EP Lab | May 18, 2018
May 18, 2018 — A significant number of patients with symptomatic premature ventricular contractions (PVCs) have under
Novel Antibiotics Can Help Lower EP Device Infection Rates. Pictured here is an ICD. Implantation of pacemakers, ICDs and the related cardiac leads opens patients to infection risk.

Implantation of pacemakers, ICDs and the related cardiac leads opens patients to infection risk.

News | EP Lab | May 17, 2018
May 10, 2018 – A new study is the first to test the clinical effectiveness of incremental peri-operative antibiotics
The Apple Watch Series 2, Samsung Galaxy Gear S3 and the Fitbit Charge 2 were all able to properly diagnose the very rapid heart beats involved in  paroxysmal supraventricular tachycardia (PSVT). #HRS2018

The Apple Watch Series 2, Samsung Galaxy Gear S3 and the Fitbit Charge 2 were all able to properly diagnose the very rapid heart beats involved in  paroxysmal supraventricular tachycardia (PSVT).  

News | EP Lab | May 16, 2018
May 16, 2018 — A new study is the first to validate the accuracy of wrist-worn wearable devices in measuring induced
LivaNova Completes Sale of Cardiac Rhythm Management (CRM - electrophysiology) Business to MicroPort Scientific
News | EP Lab | April 30, 2018
April 30, 2018 — LivaNova announced it completed the sale of its cardiac rhythm management (CRM) business to MicroPor
Overlay Init